Navigation Links
Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon

es than the Pegasys treatment group. Among heavier patients (>75 kg) who were treatment-adherent, 71.2% of those in the combined groups receiving Albuferon every two weeks achieved SVR, versus 53.3% for patients receiving Pegasys once a week. The ability to maintain efficacy in heavier patients is of particular importance in certain markets, including the United States, where a large percentage of patients weigh more than 75 kg.

Top-Line Final Results by Treatment Group

The top-line final results of the Phase 2b trial at Week 24 following the completion of therapy include the following SVR rates and other findings:

    Albuferon 900-mcg Every Two Weeks (Albuferon 900 Q2w)


    -- Based on an intention-to-treat (ITT) analysis, 58.5% of patients in the

       Albuferon 900 Q2w treatment group achieved SVR, vs. 57.9% for Pegasys

       administered every week.

    -- In heavier patients (>75 kg) who were treatment-adherent, 74.2% of

       those in the Albuferon 900 Q2w treatment group achieved SVR, versus

       53.3% for Pegasys.

    -- Among all treatment-adherent patients in the Albuferon 900 Q2w

       treatment group, 72.3% achieved SVR, versus 66.7% for Pegasys.

    -- Based on the SF-36 Health Survey, patients in the Albuferon 900 Q2w

       treatment group reported less impairment of health-related quality of

       life, compared with patients in the Pegasys treatment group, as

       measured by both physical component and mental component SF-36 summary

       measures at all time-points throughout the 48-week treatment period.

    -- Fewer working patients in the Albuferon 900 Q2w treatment group

       reported missing 7 days or more of work during the month prior to their

       visits at Weeks 12 and 24, vs. the Pegasys group (Week 12:  3.0% for

       Albuferon 900 Q2w vs. 19.2% for Pegasys; Week 24:  5.8% for Albuferon

       900 Q2w, vs. 22.4% for Pegasys).

    -- The rate of discontinuations due to adverse e
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, 2014 ... ; AEX: PHIA) and Volcano Corporation (NASDAQ: VOLC ... for cardiovascular applications, today announced that they have entered into ... commence a tender offer to acquire all of the issued ... or a total equity purchase price of USD 1 billion ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
... Spanish drug companies face a number of obstacles ...  From regulatory (FDA) and GMP compliance, to distribution agreements ... areas that must be coordinated.  Those issues have just ... U.S. company VPCI have entered into a joint association. ...
... Sherpa Clinical Packaging, a privately held provider of ... cutting ceremony today to mark the opening of ... San Diego, CA.  Sherpa,s employees and invited guests ... adjacent to the Althea Technologies campus in Sorrento ...
Cached Medicine Technology:Spanish Drug Companies Have New Support Option for the U.S. Market 2Sherpa Clinical Packaging Completes New Production Facility 2
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, ... The business has drastically cut prices to all its ... until Jan. 30, 2015. Many of the hottest styles ... dresses, lace dresses, and more. , A spokesman for ... day. Whether A-line princess prom dresses or sweetheart chiffon ...
(Date:12/20/2014)... 2014 The print component of Healthy ... distribution of approximately 160,000 copies and an estimated readership ... a vast social media strategy and across a network ... the digital version of the campaign, click here ... with the ladies of CTV’s The Social. Lainey ...
(Date:12/20/2014)... New York (PRWEB) December 20, 2014 ... continue to move forward in U.S. courts, Bernstein ... study which suggests that children treated with the ... hormone linked to breast development and lactation. The ... at 34 children and adolescents who began treatment ...
(Date:12/20/2014)... Columbus, OH (PRWEB) December 20, 2014 ... contend they suffered uncontrollable bleeding and other ... District Court, Eastern District of Louisiana for coordinated pretrial ... Panel on Multidistrict Litigation (JPML) issued an order Friday ... tag-along actions pending in 22 federal courts to the ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with ... put to the wayside until Christmas and the New Year ... “itch” and that burning desire to just escape it all ... journey to Telluride with a no-fuss, affordable package. Montrose Days ... the resort, and ensure that all accommodations are met. Plus, ...
Breaking Medicine News(10 mins):Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2
... Harris ... , ... 2009 -- Harris Williams & Co. is pleased to announce that Verathon Inc., a portfolio ... buyer Roper Industries (NYSE: ROP). Harris Williams & Co. acted as the exclusive advisor ...
... , HOLMDEL, ... Sparta Systems, Inc., the maker of TrackWise (®) software ... solutions, is pleased to announce new additions to the TrackWise ... Medical Device Vigilance reporting. The addition of ClinicalTrials.gov reporting ...
... , , , ... Quality Alliance (MTQUA, http://www.mtqua.org ), announces the first ... medical travel providers worldwide. , "All medical tourists who want ... medical travel with a Certified International Patient Advisor (CIPA) and ...
... 2010 AIUM Annual Convention and Preconvention Program, the only ... all disciplines of medical ultrasound, to be held March ... Convention focuses on emerging applications and unique opportunities for ... continues to advance and expand into new arenas. ...
... not being vaccinated against the seasonal flu any more often ... the importance of influenza vaccines resulting from the worldwide outbreak ... study. As of the middle of November, about 32 ... recommended to receive a flu vaccination had been inoculated against ...
... Finding is good news for first-line treatment in Africa, researchers ... finding that has implications for how the AIDS virus is ... be given without routine monitoring by lab tests. , But ... to monitor the progression of the disease and guide the ...
Cached Medicine News:Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 2Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 3Health News:TrackWise(R) Electronic Regulatory Reporting Solution Enables Companies to Meet Current and Future Mandates 2Health News:TrackWise(R) Electronic Regulatory Reporting Solution Enables Companies to Meet Current and Future Mandates 3Health News:Medical Travel Quality Alliance to Certify Medical Tourism Agents for Safer, Quality Health Care for Traveling International Patients 2Health News:AIUM gears up for 2010 Annual Convention in San Diego, Calif. 2Health News:American adults receiving flu vaccine at about the same rate as in 2008, study finds 2Health News:American adults receiving flu vaccine at about the same rate as in 2008, study finds 3
... This compact system provides an ... preparation in the laboratory, satellite lab ... proven HEMA-TEK staining method with wedge-smear ... delivers complete standardization in a safe ...
It is a cardio-pulmonary exercise testing device....
... has digitally-controlled drive system which eliminates ... can wear out. There are no ... and fewer drive belts - resulting ... It can carry weights up to ...
... systems feature our internationally-acclaimed algorithm that ... algorithm has a proven record for ... situations; and it's just one of ... recognized market leader in the stress ...
Medicine Products: